Abstract: The invention relates to a nasally administrable composition comprising at least one active substance in magnesium-containing vesicular carrier, said carrier comprising glycol, phospholipids, water and at least one magnesium source. Methods for nasal administration of the composition, for example, for pain relief, are also provided.

Abstract: A medical system including a tube defining a lumen, a porous body connected to a distal end of the tube to be advanced to a target site within a subject. The porous body defines a plurality of openings, the plurality of openings are in fluid connection with the lumen, the porous body includes a first material and a second material, and the second material elutes from the porous body in the subject.

Abstract: A prosthetic implant, suitable for implantation to the human body, comprising a shell and a gel filling, wherein the shell comprises an innermost layer and at least an additional layer; wherein the innermost layer is in contact with the gel; wherein the innermost layer is adapted to adhere to said gel.

Abstract: Described herein are essential oils, extracts, apparatus and methods for the extraction of the essential oils and extracts from plant biomass using microwaves.

Abstract: The invention relates to malodor masking compositions and/or ingredients, methods for counteracting or masking malodors, and perfuming compositions having odor masking properties comprising 2, 4-dialkyl substituted pyridines for formula (I).

Abstract: The present disclosure relates the polymer compositions, fibers, and yarns having near-permanent antimicrobial activity, and a method of producing the same. In one embodiment, the antimicrobial polymer composition from 50 wt % to 99.9 wt % of a polymer, from 5 wppm to 1000 wppm of zinc, and from 0.005 wt % to 1 wt % of phosphorus, wherein fibers formed from the polymer composition demonstrate a zinc retention rate of greater than 20% when tested in a dye bath test.

Abstract: The present invention relates to a novel pharmaceutical use of bromide, i.e. the treatment of autism spectral disorder (ASD).

Abstract: A method of reducing the appearance of hyperpigmented skin is disclosed. The method can include topically applying to hyperpigmented skin a composition comprising an aqueous and/or glycerin extract of Rhododendron ferrugineum leaf to reduce melanocyte pigmentation in the skin.

Abstract: A method for managing skin tone comprising reducing the synthesis of melanin by applying a skin treatment composition to skin. The skin treatment composition may include about 0.1 to about 25 wt. % of acetyl trifluoromethylphenyl valylglycine; about 0.5 to about 30 wt. % of a polyol; about 0.1 to about 30 wt. % of a silicone, fatty compound, or a mixtures thereof, wherein the skin treatment composition is an emulsion, and all weight percentages are based on the total weight of the skin treatment composition.

Abstract: The present invention relates to a topical formulation intended to be used for the treatment of androgenic or androgenetic baldness is men and women, with reduced side effects, especially with fewer collateral effects in the female population. The topical formulation comprises 0.01% to 10% by weight of Finasteride and a concentration of 1% to 5% by weight of Minoxidil in its free form or in an inert porous polymer. The combination of Finasteride and Minoxidil provides a synergistic effect against baldness. The formulation also comprises 0.15% by weight of retinol and is suitable for being applied to the scalp of the patient that requires it.

Abstract: The present invention relates to a multilayer UV filter particle, comprising: an odd number of alternating layers of high and low refractive index materials, wherein each layer has a refractive index that differs from that of adjacent layers by at least 0.2, the total number of layers is at least 9, and the particle does not contain a substrate. The particle according to the present invention can have a good UV filtering effect.

Abstract: Disclosed herein is a scalp protection composition that includes a carboxylate compound, an emulsifier, and water. The carboxylate compound is represented by formula (I): In formula (I), R1 represents a C4-C8 alkyl group, and R2 represents a C10-C26 alkyl group.

Abstract: The present disclosure relates to the field of perfumery and more precisely it concerns a deodorant or an antiperspirant composition comprising a ?-thio carbonyl profragrance. The use of the composition to reduce body odour and a dispensing container comprising the composition are also objects of the disclosure.

Abstract: A hydrogen-enhanced drug delivery system for hydrogen-assisted transdermal delivery of a therapeutic agent is provided. The system includes a hydrogen-generating compartment comprising at least one dry chemical. Addition of an activator, such as a liquid composition, from within or outside of the system, causes the dry chemical(s) to generate molecular hydrogen (H2) within the system. The molecular hydrogen passes through a skin-contacting surface of the system, which is permeable to hydrogen and not permeable to the dry chemical(s) and the liquid composition, and enhances the release of the therapeutic agent from the system as H2 is delivered to the subject's body. The H2 can also enhance the therapeutic effect of the therapeutic agent.

Abstract: The present invention relates to a solid pharmaceutical formulation comprising misoprostol or a pharmaceutically acceptable salt thereof. In particular, the invention relates to a dispersible tablet comprising misoprostol or a pharmaceutically acceptable salt thereof, providing alternative routes of administration. The tablet is particularly suited for cervical ripening, induction of labor, prevention and/or treatment of postpartum or post-abortion hemorrhage.

Abstract: The present invention discloses a method for maintaining or improving gastrointestinal condition, which includes: administering a lactic acid bacterial composition to a subject in need thereof, wherein the lactic acid bacterial composition comprises: a Lactobacillus paracasei ET-66 strain with a deposition number CGMCC 13514. The present invention also discloses a method for maintaining or improving gastrointestinal condition, which includes: administering a lactic acid bacterial fermentation composition to a subject in need thereof, wherein the lactic acid bacterial fermentation composition comprises: a fermentation product of a Lactobacillus paracasei ET-66 strain.

Abstract: The present invention is a cardioplegic solution that demonstrates better stability in pH, particulate matter formation and osmolality but at the same time demonstrates superior ability to preserve heart functions than currently available cardioplegic solutions. The cardioplegic solution comprises potassium (K+), magnesium (Mg2+), sodium (Na+), chloride (Cl?), gluconate, acetate, sulfate (SO42?), THAM and mannitol dissolved in water.

Abstract: To provide a bioimplant capable of controlling a rate of an antibacterial agent and an antibiotic to be eluted from the coating film. An evanescent coating film made of a calcium phosphate-based material having crystallinity of 10% to 90% is formed at a predetermined area of the bioimplant and an antibacterial agent or an antibiotic is contained in the coating film to suppress adhesion of bacteria.

Abstract: The present invention relates to topical compositions comprising at least one liquid UV-filter and a nano-sized 1,4-di(benzoxazol-2?-yl)benzene.

Abstract: Disclosed herein are immediate release oral dosage forms that contain abuse-deterrent and abuse-resistant features. In particular, the disclosed dosage forms can provide deterrence of abuse by ingestion of multiple individual doses. The disclosed dosage forms can likewise provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses. The dosage forms may also exhibit abuse resistant properties when physically manipulated, and also when physically manipulated and then administered in a manner not consistent with oral dosing. The dosage forms may also exhibit abuse resistant properties when administered in a manner intended to result in administration of the esketamine in a higher than therapeutic dose.